# A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

> **NCT03025542** · PHASE2 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 49 (actual)

## Conditions studied

- Chronic Plaque Psoriasis

## Interventions

- **DRUG:** Bimekizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03025542
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-27
- **Primary completion:** 2017-12-11
- **Final completion:** 2017-12-11
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03025542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03025542, "A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03025542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*